Calls to relax UK medical cannabis rules, especially for mental health patients, are growing as evidence and patient experience highlight both benefits and risks. Since legalization of cannabis‑based medicinal products (CBMPs) in 2018, very few NHS prescriptions have been issued, creating a stark gap between law and real access.

     Surveys suggest more than a million people use illicit cannabis for medical reasons, often because they cannot obtain prescriptions despite symptom relief. Qualitative interviews with UK patients prescribed cannabis report substantial improvements in mental and physical health, reduced use of conventional drugs, and relatively few side effects, yet also describe stigma, bureaucratic hurdles, and fear of criminalisation when using their medicine in public. 

     Supporters of reform argue that for conditions like chronic pain, anxiety, PTSD and other mental health problems, cannabinoids can improve wellbeing and quality of life, particularly when other treatments have failed. Registry data from UK patients across chronic conditions show improved health‑related quality of life, anxiety and sleep after starting CBMPs, with most tolerating treatment reasonably well.

    Campaigners say current guidance is overly restrictive, specialist‑only prescribing and conservative NICE recommendations mean that “no or very few” NHS patients have truly benefited, pushing desperate people to the black market .  Critics emphasise that high‑THC cannabis increases the risk of psychosis and other mental health problems, while overall European data show rising cannabis use, potency and treatment for cannabis‑related disorders 

     Professional bodies warn that evidence remains limited for many psychiatric indications and insist on careful monitoring, last‑resort use and strong safeguards against misuse.  An evidence‑based reform path would likely mean clearer prescribing criteria for mental health conditions, better clinician training, robust patient‑reported outcome monitoring and harm‑reduction rules that expand access while actively managing psychosis and dependence risks